Ensign Peak Advisors’s Summit Therapeutics SMMT Stock Holding History

Ensign Peak Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-151,000	Closed	-$2.91M	–	1718
2025 Q1	$2.91M	Buy	+151,000	New	+$3.03M	0.01%	776

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ensign Peak Advisors's SMMT Position: Q2 2025 in Review

Ensign Peak Advisors sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 151,000 shares — an estimated $2.91M sold.

Ensign Peak Advisors first reported a position in SMMT in Q1 2025 and held it in 1 quarter. The position peaked at $2.91M in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

Ensign Peak Advisors reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
Ensign Peak Advisors sold 151,000 Summit Therapeutics shares in Q2 2025, an estimated $2.91M.
Ensign Peak Advisors first reported a position in Summit Therapeutics in Q1 2025 and held it in 1 quarter.
Ensign Peak Advisors's Summit Therapeutics position peaked at $2.91M in Q1 2025.
238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Ensign Peak Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.